Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Greenhill Gains as Firm Plays Adviser to Actavis

Don't Miss Out —
Follow us on:

Feb. 18 (Bloomberg) -- Greenhill & Co. gained the most in more than two years after the firm acted as sole adviser to Actavis Plc in its $25 billion bid for Forest Laboratories Inc.

Greenhill, founded by former Morgan Stanley President Robert F. Greenhill, rose 8.7 percent to $52.98 at 4:15 p.m. in New York. The rally buoyed the stock after a 16 percent slide this year through last week, following a fourth quarter that included a 25 percent drop in advisory revenue.

“There was definitely a great deal of relief to see them on a large deal,” said Brennan Hawken, an analyst at UBS AG, who assigns a neutral rating to the stock. “Often when you have a deal that big, there is more than one adviser. They are getting all the revenue on the buy side.”

Hawken said the stock had become a target of short-sellers, who are probably buying today to cut their losses after betting on a further decline. Jeffrey Taufield, Greenhill’s spokesman, said in an e-mail that the company had no comment.

Actavis, the world’s second-largest generic-drug maker by market value, is seeking to become a developer of brand-name drugs.

To contact the reporter on this story: Sarah Jacob in New York at

To contact the editor responsible for this story: Rick Green at